A prospective, 96-week study of the impact of Trizivir super( registered ), Combivir super( registered )-nelfinavir, and lamivudine-stavudine-nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

A prospective, 96-week study of the impact of Trizivir super( registered ), Combivir super( registered )-nelfinavir, and lamivudine-stavudine-nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

Objectives: To compare the lipid and metabolic effects, efficacy, and safety of twice-daily regimens of Trizivir super( registered ) (abacavir 300 mg-lamivudine 150 mg-zidovudine 300 mg triple nucleoside tablet; TZV), Combivir super( registered ) (lamivudine 150 mg-zidovudine 300 mg combination tabl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HIV medicine 2006-03, Vol.7 (2), p.85-98
Hauptverfasser: Kumar, P N, Rodriguez-French, A, Thompson, MA, Tashima, K T, Averitt, D, Wannamaker, P G, Williams, V C, Shaefer, MS, Pakes, GE, Pappa, KA
Format: Artikel
Sprache:eng
Schlagworte:
Human immunodeficiency virus 1
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 98
container_issue 2
container_start_page 85
container_title HIV medicine
container_volume 7
creator Kumar, P N
Rodriguez-French, A
Thompson, MA
Tashima, K T
Averitt, D
Wannamaker, P G
Williams, V C
Shaefer, MS
Pakes, GE
Pappa, KA
description Objectives: To compare the lipid and metabolic effects, efficacy, and safety of twice-daily regimens of Trizivir super( registered ) (abacavir 300 mg-lamivudine 150 mg-zidovudine 300 mg triple nucleoside tablet; TZV), Combivir super( registered ) (lamivudine 150 mg-zidovudine 300 mg combination tablet; COM)+nelfinavir (NFV), and stavudine (d4 T)+lamivudine (3TC)+NFV. Study design: An international, phase 4, open-label, parallel-group, 34-centre study was conducted in 254 non-diabetic, antiretroviral-naive, HIV-infected out-patients with an HIV-1 RNA level of >1000 HIV-1 RNA copies-mL and less than or equal to 200 000 copies-mL and a CD4 cell count of >50 cells- mu L. Methods: Patients were randomized 1 : 1 : 1 to TZV twice daily (n=85), COM-NFV 1250 mg twice daily (n=88), or d4T 40 mg+3TC 150 mg+NFV 1250 mg twice daily (n=81) for 96 weeks. Treatments were compared using analysis of covariance (ANCOVA) with regard to changes from baseline in fasting lipids in the total population and in sex and ethnic subgroups. The proportions of patients achieving HIV-1 RNA
doi_str_mv 10.1111/j.1468-1293.2006.00346.x
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_17121198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17121198</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_171211983</originalsourceid><addsrcrecordid>eNqNUMtOwzAQDC-J8viHPSGQ4mAnVdpwQxWID-i9cpMN3eI4weuUlq-v-xCckNjLzmhmVpqNIlAyUWEel4ka5mOh0iJLUinzRMpsmCfr02jwI5zv8VCkeZ5eRlfMSynVKCvk4OTsGTrXcoelpxXGUOTiC_ED2PfVBtoa_AKBmk6Xfsemjr5pRQ6479Ddg8N3Yo8OK3iIYdI2879UYdHUZHWQY9C2AqMbWvUVWRTs9RH9mqC1YKijimNo0Ot5a6iETjsdGDre38C6plKXGyAbuCeH3rUhrI2wOvQJfk9oPT_trHjowLg-hP3CUkl-cxNd1Now3h73dXT3-jKdvInwmc8e2c8a4hKN0RbbnmdqpFKlinH2b-MWysiLpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17121198</pqid></control><display><type>article</type><title>A prospective, 96-week study of the impact of Trizivir super( registered ), Combivir super( registered )-nelfinavir, and lamivudine-stavudine-nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity</title><source>IngentaConnect Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kumar, P N ; Rodriguez-French, A ; Thompson, MA ; Tashima, K T ; Averitt, D ; Wannamaker, P G ; Williams, V C ; Shaefer, MS ; Pakes, GE ; Pappa, KA</creator><creatorcontrib>Kumar, P N ; Rodriguez-French, A ; Thompson, MA ; Tashima, K T ; Averitt, D ; Wannamaker, P G ; Williams, V C ; Shaefer, MS ; Pakes, GE ; Pappa, KA</creatorcontrib><description>Objectives: To compare the lipid and metabolic effects, efficacy, and safety of twice-daily regimens of Trizivir super( registered ) (abacavir 300 mg-lamivudine 150 mg-zidovudine 300 mg triple nucleoside tablet; TZV), Combivir super( registered ) (lamivudine 150 mg-zidovudine 300 mg combination tablet; COM)+nelfinavir (NFV), and stavudine (d4 T)+lamivudine (3TC)+NFV. Study design: An international, phase 4, open-label, parallel-group, 34-centre study was conducted in 254 non-diabetic, antiretroviral-naive, HIV-infected out-patients with an HIV-1 RNA level of &gt;1000 HIV-1 RNA copies-mL and less than or equal to 200 000 copies-mL and a CD4 cell count of &gt;50 cells- mu L. Methods: Patients were randomized 1 : 1 : 1 to TZV twice daily (n=85), COM-NFV 1250 mg twice daily (n=88), or d4T 40 mg+3TC 150 mg+NFV 1250 mg twice daily (n=81) for 96 weeks. Treatments were compared using analysis of covariance (ANCOVA) with regard to changes from baseline in fasting lipids in the total population and in sex and ethnic subgroups. The proportions of patients achieving HIV-1 RNA &lt;50 and &lt;400 copies-mL were compared using a 95% confidence interval (CI) on the difference between proportions. Results: The study population was diverse (50% female, 40% black and 37% Hispanic). Mean baseline low-density lipoprotein (LDL) cholesterol was 99 mg-dL, HIV-1 RNA was 4.43 log sub(10) copies-mL and CD4 cell count was 355 cells- mu L. At week 96, fasting LDL cholesterol changed minimally in the TZV group [least square mean (LSM) change from baseline, -8 mg-dL], but increased with d4T-3TC-NFV and COM-NFV (+29 and +19 mg-dL, respectively; P&lt;0.001 versus TZV). Week 96 LDL-cholesterol levels were significantly lower in the TZV group than in the other two treatment groups in women and men and lower than in the d4T-3TC-NFV group in Hispanic and black patients. In black patients, the week-96 LSM change from baseline in LDL cholesterol was significantly less with TZV than with d4T-3TC-NFV (+1 vs+39 mg-dL; P=0.003). Total cholesterol&gt;200 mg-dL occurred in a smaller proportion of patients receiving TZV (30%) compared with COM-NFV (50%) or d4T-3TC-NFV (60%; P=0.005 vs TZV). High-density lipoprotein (HDL) cholesterol did not change markedly with any treatment. Although triglycerides increased, they changed least in women and Hispanic patients receiving TZV. Virological and CD4 responses to the treatments were similar in the total population and in the subgroups. Diarrhoea was reported more often in the NFV arms and nausea in the ZDV arms. Conclusions: Over 96 weeks, TZV twice daily has significantly less effect on LDL cholesterol than COM-NFV or d4T-3TC-NFV twice daily, especially in women and black patients, and is associated with similar virological and CD4 responses.</description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/j.1468-1293.2006.00346.x</identifier><language>eng</language><subject>Human immunodeficiency virus 1</subject><ispartof>HIV medicine, 2006-03, Vol.7 (2), p.85-98</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Kumar, P N</creatorcontrib><creatorcontrib>Rodriguez-French, A</creatorcontrib><creatorcontrib>Thompson, MA</creatorcontrib><creatorcontrib>Tashima, K T</creatorcontrib><creatorcontrib>Averitt, D</creatorcontrib><creatorcontrib>Wannamaker, P G</creatorcontrib><creatorcontrib>Williams, V C</creatorcontrib><creatorcontrib>Shaefer, MS</creatorcontrib><creatorcontrib>Pakes, GE</creatorcontrib><creatorcontrib>Pappa, KA</creatorcontrib><title>A prospective, 96-week study of the impact of Trizivir super( registered ), Combivir super( registered )-nelfinavir, and lamivudine-stavudine-nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity</title><title>HIV medicine</title><description>Objectives: To compare the lipid and metabolic effects, efficacy, and safety of twice-daily regimens of Trizivir super( registered ) (abacavir 300 mg-lamivudine 150 mg-zidovudine 300 mg triple nucleoside tablet; TZV), Combivir super( registered ) (lamivudine 150 mg-zidovudine 300 mg combination tablet; COM)+nelfinavir (NFV), and stavudine (d4 T)+lamivudine (3TC)+NFV. Study design: An international, phase 4, open-label, parallel-group, 34-centre study was conducted in 254 non-diabetic, antiretroviral-naive, HIV-infected out-patients with an HIV-1 RNA level of &gt;1000 HIV-1 RNA copies-mL and less than or equal to 200 000 copies-mL and a CD4 cell count of &gt;50 cells- mu L. Methods: Patients were randomized 1 : 1 : 1 to TZV twice daily (n=85), COM-NFV 1250 mg twice daily (n=88), or d4T 40 mg+3TC 150 mg+NFV 1250 mg twice daily (n=81) for 96 weeks. Treatments were compared using analysis of covariance (ANCOVA) with regard to changes from baseline in fasting lipids in the total population and in sex and ethnic subgroups. The proportions of patients achieving HIV-1 RNA &lt;50 and &lt;400 copies-mL were compared using a 95% confidence interval (CI) on the difference between proportions. Results: The study population was diverse (50% female, 40% black and 37% Hispanic). Mean baseline low-density lipoprotein (LDL) cholesterol was 99 mg-dL, HIV-1 RNA was 4.43 log sub(10) copies-mL and CD4 cell count was 355 cells- mu L. At week 96, fasting LDL cholesterol changed minimally in the TZV group [least square mean (LSM) change from baseline, -8 mg-dL], but increased with d4T-3TC-NFV and COM-NFV (+29 and +19 mg-dL, respectively; P&lt;0.001 versus TZV). Week 96 LDL-cholesterol levels were significantly lower in the TZV group than in the other two treatment groups in women and men and lower than in the d4T-3TC-NFV group in Hispanic and black patients. In black patients, the week-96 LSM change from baseline in LDL cholesterol was significantly less with TZV than with d4T-3TC-NFV (+1 vs+39 mg-dL; P=0.003). Total cholesterol&gt;200 mg-dL occurred in a smaller proportion of patients receiving TZV (30%) compared with COM-NFV (50%) or d4T-3TC-NFV (60%; P=0.005 vs TZV). High-density lipoprotein (HDL) cholesterol did not change markedly with any treatment. Although triglycerides increased, they changed least in women and Hispanic patients receiving TZV. Virological and CD4 responses to the treatments were similar in the total population and in the subgroups. Diarrhoea was reported more often in the NFV arms and nausea in the ZDV arms. Conclusions: Over 96 weeks, TZV twice daily has significantly less effect on LDL cholesterol than COM-NFV or d4T-3TC-NFV twice daily, especially in women and black patients, and is associated with similar virological and CD4 responses.</description><subject>Human immunodeficiency virus 1</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNUMtOwzAQDC-J8viHPSGQ4mAnVdpwQxWID-i9cpMN3eI4weuUlq-v-xCckNjLzmhmVpqNIlAyUWEel4ka5mOh0iJLUinzRMpsmCfr02jwI5zv8VCkeZ5eRlfMSynVKCvk4OTsGTrXcoelpxXGUOTiC_ED2PfVBtoa_AKBmk6Xfsemjr5pRQ6479Ddg8N3Yo8OK3iIYdI2879UYdHUZHWQY9C2AqMbWvUVWRTs9RH9mqC1YKijimNo0Ot5a6iETjsdGDre38C6plKXGyAbuCeH3rUhrI2wOvQJfk9oPT_trHjowLg-hP3CUkl-cxNd1Now3h73dXT3-jKdvInwmc8e2c8a4hKN0RbbnmdqpFKlinH2b-MWysiLpA</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Kumar, P N</creator><creator>Rodriguez-French, A</creator><creator>Thompson, MA</creator><creator>Tashima, K T</creator><creator>Averitt, D</creator><creator>Wannamaker, P G</creator><creator>Williams, V C</creator><creator>Shaefer, MS</creator><creator>Pakes, GE</creator><creator>Pappa, KA</creator><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20060301</creationdate><title>A prospective, 96-week study of the impact of Trizivir super( registered ), Combivir super( registered )-nelfinavir, and lamivudine-stavudine-nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity</title><author>Kumar, P N ; Rodriguez-French, A ; Thompson, MA ; Tashima, K T ; Averitt, D ; Wannamaker, P G ; Williams, V C ; Shaefer, MS ; Pakes, GE ; Pappa, KA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_171211983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Human immunodeficiency virus 1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, P N</creatorcontrib><creatorcontrib>Rodriguez-French, A</creatorcontrib><creatorcontrib>Thompson, MA</creatorcontrib><creatorcontrib>Tashima, K T</creatorcontrib><creatorcontrib>Averitt, D</creatorcontrib><creatorcontrib>Wannamaker, P G</creatorcontrib><creatorcontrib>Williams, V C</creatorcontrib><creatorcontrib>Shaefer, MS</creatorcontrib><creatorcontrib>Pakes, GE</creatorcontrib><creatorcontrib>Pappa, KA</creatorcontrib><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, P N</au><au>Rodriguez-French, A</au><au>Thompson, MA</au><au>Tashima, K T</au><au>Averitt, D</au><au>Wannamaker, P G</au><au>Williams, V C</au><au>Shaefer, MS</au><au>Pakes, GE</au><au>Pappa, KA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective, 96-week study of the impact of Trizivir super( registered ), Combivir super( registered )-nelfinavir, and lamivudine-stavudine-nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity</atitle><jtitle>HIV medicine</jtitle><date>2006-03-01</date><risdate>2006</risdate><volume>7</volume><issue>2</issue><spage>85</spage><epage>98</epage><pages>85-98</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract>Objectives: To compare the lipid and metabolic effects, efficacy, and safety of twice-daily regimens of Trizivir super( registered ) (abacavir 300 mg-lamivudine 150 mg-zidovudine 300 mg triple nucleoside tablet; TZV), Combivir super( registered ) (lamivudine 150 mg-zidovudine 300 mg combination tablet; COM)+nelfinavir (NFV), and stavudine (d4 T)+lamivudine (3TC)+NFV. Study design: An international, phase 4, open-label, parallel-group, 34-centre study was conducted in 254 non-diabetic, antiretroviral-naive, HIV-infected out-patients with an HIV-1 RNA level of &gt;1000 HIV-1 RNA copies-mL and less than or equal to 200 000 copies-mL and a CD4 cell count of &gt;50 cells- mu L. Methods: Patients were randomized 1 : 1 : 1 to TZV twice daily (n=85), COM-NFV 1250 mg twice daily (n=88), or d4T 40 mg+3TC 150 mg+NFV 1250 mg twice daily (n=81) for 96 weeks. Treatments were compared using analysis of covariance (ANCOVA) with regard to changes from baseline in fasting lipids in the total population and in sex and ethnic subgroups. The proportions of patients achieving HIV-1 RNA &lt;50 and &lt;400 copies-mL were compared using a 95% confidence interval (CI) on the difference between proportions. Results: The study population was diverse (50% female, 40% black and 37% Hispanic). Mean baseline low-density lipoprotein (LDL) cholesterol was 99 mg-dL, HIV-1 RNA was 4.43 log sub(10) copies-mL and CD4 cell count was 355 cells- mu L. At week 96, fasting LDL cholesterol changed minimally in the TZV group [least square mean (LSM) change from baseline, -8 mg-dL], but increased with d4T-3TC-NFV and COM-NFV (+29 and +19 mg-dL, respectively; P&lt;0.001 versus TZV). Week 96 LDL-cholesterol levels were significantly lower in the TZV group than in the other two treatment groups in women and men and lower than in the d4T-3TC-NFV group in Hispanic and black patients. In black patients, the week-96 LSM change from baseline in LDL cholesterol was significantly less with TZV than with d4T-3TC-NFV (+1 vs+39 mg-dL; P=0.003). Total cholesterol&gt;200 mg-dL occurred in a smaller proportion of patients receiving TZV (30%) compared with COM-NFV (50%) or d4T-3TC-NFV (60%; P=0.005 vs TZV). High-density lipoprotein (HDL) cholesterol did not change markedly with any treatment. Although triglycerides increased, they changed least in women and Hispanic patients receiving TZV. Virological and CD4 responses to the treatments were similar in the total population and in the subgroups. Diarrhoea was reported more often in the NFV arms and nausea in the ZDV arms. Conclusions: Over 96 weeks, TZV twice daily has significantly less effect on LDL cholesterol than COM-NFV or d4T-3TC-NFV twice daily, especially in women and black patients, and is associated with similar virological and CD4 responses.</abstract><doi>10.1111/j.1468-1293.2006.00346.x</doi></addata></record>
fulltext fulltext
identifier ISSN: 1464-2662
ispartof HIV medicine, 2006-03, Vol.7 (2), p.85-98
issn 1464-2662
1468-1293
language eng
recordid cdi_proquest_miscellaneous_17121198
source IngentaConnect Open Access Journals; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Human immunodeficiency virus 1
title A prospective, 96-week study of the impact of Trizivir super( registered ), Combivir super( registered )-nelfinavir, and lamivudine-stavudine-nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A44%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective,%2096-week%20study%20of%20the%20impact%20of%20Trizivir%20super(%20registered%20),%20Combivir%20super(%20registered%20)-nelfinavir,%20and%20lamivudine-stavudine-nelfinavir%20on%20lipids,%20metabolic%20parameters%20and%20efficacy%20in%20antiretroviral-naive%20patients:%20effect%20of%20sex%20and%20ethnicity&rft.jtitle=HIV%20medicine&rft.au=Kumar,%20P%20N&rft.date=2006-03-01&rft.volume=7&rft.issue=2&rft.spage=85&rft.epage=98&rft.pages=85-98&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/j.1468-1293.2006.00346.x&rft_dat=%3Cproquest%3E17121198%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17121198&rft_id=info:pmid/&rfr_iscdi=true